Estradiol-sertraline synergy in ovariectomized rats

Stacy Sell, Rebecca M. Craft, Patricia K. Seitz, Sonja J. Stutz, Kathryn Cunningham, Mary L. Thomas

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

This study investigated estradiol (E2) modulation of the antidepressant effects of a selective serotonin (5-HT) reuptake inhibitor (SSRI; sertraline) and a tricyclic antidepressant (imipramine) as measured by the forced swim test (FST) followed by assessment of gene and protein expression for the 5-HT transporter (SERT) and multiple 5-HT receptors. Female Sprague-Dawley rats were ovariectomized (OVX) and two-thirds of the rats received E2 implants (OVE). 4 weeks later, implants were withdrawn in half of the OVE rats (OVW) to capture a time point when E2 levels were rapidly declining. Rats in each hormone group were treated with vehicle, sertraline (10 mg/kg) or imipramine (10 mg/kg), 24, 5 and 1 h before the FST. Immediately after the FST, midbrain, hippocampus and prefrontal cortex tissue was removed and frozen for analysis of gene expression via quantitative real-time PCR (midbrain tissue) and protein expression via Western blot (prefrontal cortex and hippocampal tissue). In the FST, sertraline decreased immobility and increased swimming in OVE rats, as well as increased swimming in OVW rats. In contrast, no sertraline effect was observed in OVX rats. Rats treated with imipramine showed increased climbing but no changes in immobility or swimming. No changes in protein expression were detected in any treatment group. However, in vehicle-treated rats, E2 increased midbrain SERT mRNA expression, with no effect on midbrain mRNA for the 5-HT receptors. In sertraline-treated rats, E2 decreased 5-HT2A receptor mRNA, and E2-withdrawal increased 5-HT1A, 5-HT2A and 5-HT2C receptor mRNA. In imipramine-treated rats, E2 (and E2-withdrawal) did not affect mRNA expression for any of the target genes. Thus, E2 synergized behaviorally and neurochemically with an SSRI but not a tricyclic antidepressant.

Original languageEnglish (US)
Pages (from-to)1051-1060
Number of pages10
JournalPsychoneuroendocrinology
Volume33
Issue number8
DOIs
StatePublished - Sep 2008

Fingerprint

Sertraline
Estradiol
Imipramine
Mesencephalon
Messenger RNA
Serotonin
Tricyclic Antidepressive Agents
Serotonin Receptors
Prefrontal Cortex
Receptor, Serotonin, 5-HT2C
Gene Expression
Receptor, Serotonin, 5-HT2A
Proteins
Antidepressive Agents
Sprague Dawley Rats
Real-Time Polymerase Chain Reaction
Hippocampus
Western Blotting
Hormones

Keywords

  • Antidepressant
  • Estrogen
  • Forced swim test
  • Selective serotonin reuptake inhibitor
  • Serotonin receptors
  • Serotonin transporter

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Endocrine and Autonomic Systems
  • Psychology(all)

Cite this

Estradiol-sertraline synergy in ovariectomized rats. / Sell, Stacy; Craft, Rebecca M.; Seitz, Patricia K.; Stutz, Sonja J.; Cunningham, Kathryn; Thomas, Mary L.

In: Psychoneuroendocrinology, Vol. 33, No. 8, 09.2008, p. 1051-1060.

Research output: Contribution to journalArticle

Sell, Stacy ; Craft, Rebecca M. ; Seitz, Patricia K. ; Stutz, Sonja J. ; Cunningham, Kathryn ; Thomas, Mary L. / Estradiol-sertraline synergy in ovariectomized rats. In: Psychoneuroendocrinology. 2008 ; Vol. 33, No. 8. pp. 1051-1060.
@article{ed00153d6f93440d96e0d2ac43bf4357,
title = "Estradiol-sertraline synergy in ovariectomized rats",
abstract = "This study investigated estradiol (E2) modulation of the antidepressant effects of a selective serotonin (5-HT) reuptake inhibitor (SSRI; sertraline) and a tricyclic antidepressant (imipramine) as measured by the forced swim test (FST) followed by assessment of gene and protein expression for the 5-HT transporter (SERT) and multiple 5-HT receptors. Female Sprague-Dawley rats were ovariectomized (OVX) and two-thirds of the rats received E2 implants (OVE). 4 weeks later, implants were withdrawn in half of the OVE rats (OVW) to capture a time point when E2 levels were rapidly declining. Rats in each hormone group were treated with vehicle, sertraline (10 mg/kg) or imipramine (10 mg/kg), 24, 5 and 1 h before the FST. Immediately after the FST, midbrain, hippocampus and prefrontal cortex tissue was removed and frozen for analysis of gene expression via quantitative real-time PCR (midbrain tissue) and protein expression via Western blot (prefrontal cortex and hippocampal tissue). In the FST, sertraline decreased immobility and increased swimming in OVE rats, as well as increased swimming in OVW rats. In contrast, no sertraline effect was observed in OVX rats. Rats treated with imipramine showed increased climbing but no changes in immobility or swimming. No changes in protein expression were detected in any treatment group. However, in vehicle-treated rats, E2 increased midbrain SERT mRNA expression, with no effect on midbrain mRNA for the 5-HT receptors. In sertraline-treated rats, E2 decreased 5-HT2A receptor mRNA, and E2-withdrawal increased 5-HT1A, 5-HT2A and 5-HT2C receptor mRNA. In imipramine-treated rats, E2 (and E2-withdrawal) did not affect mRNA expression for any of the target genes. Thus, E2 synergized behaviorally and neurochemically with an SSRI but not a tricyclic antidepressant.",
keywords = "Antidepressant, Estrogen, Forced swim test, Selective serotonin reuptake inhibitor, Serotonin receptors, Serotonin transporter",
author = "Stacy Sell and Craft, {Rebecca M.} and Seitz, {Patricia K.} and Stutz, {Sonja J.} and Kathryn Cunningham and Thomas, {Mary L.}",
year = "2008",
month = "9",
doi = "10.1016/j.psyneuen.2008.05.006",
language = "English (US)",
volume = "33",
pages = "1051--1060",
journal = "Psychoneuroendocrinology",
issn = "0306-4530",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Estradiol-sertraline synergy in ovariectomized rats

AU - Sell, Stacy

AU - Craft, Rebecca M.

AU - Seitz, Patricia K.

AU - Stutz, Sonja J.

AU - Cunningham, Kathryn

AU - Thomas, Mary L.

PY - 2008/9

Y1 - 2008/9

N2 - This study investigated estradiol (E2) modulation of the antidepressant effects of a selective serotonin (5-HT) reuptake inhibitor (SSRI; sertraline) and a tricyclic antidepressant (imipramine) as measured by the forced swim test (FST) followed by assessment of gene and protein expression for the 5-HT transporter (SERT) and multiple 5-HT receptors. Female Sprague-Dawley rats were ovariectomized (OVX) and two-thirds of the rats received E2 implants (OVE). 4 weeks later, implants were withdrawn in half of the OVE rats (OVW) to capture a time point when E2 levels were rapidly declining. Rats in each hormone group were treated with vehicle, sertraline (10 mg/kg) or imipramine (10 mg/kg), 24, 5 and 1 h before the FST. Immediately after the FST, midbrain, hippocampus and prefrontal cortex tissue was removed and frozen for analysis of gene expression via quantitative real-time PCR (midbrain tissue) and protein expression via Western blot (prefrontal cortex and hippocampal tissue). In the FST, sertraline decreased immobility and increased swimming in OVE rats, as well as increased swimming in OVW rats. In contrast, no sertraline effect was observed in OVX rats. Rats treated with imipramine showed increased climbing but no changes in immobility or swimming. No changes in protein expression were detected in any treatment group. However, in vehicle-treated rats, E2 increased midbrain SERT mRNA expression, with no effect on midbrain mRNA for the 5-HT receptors. In sertraline-treated rats, E2 decreased 5-HT2A receptor mRNA, and E2-withdrawal increased 5-HT1A, 5-HT2A and 5-HT2C receptor mRNA. In imipramine-treated rats, E2 (and E2-withdrawal) did not affect mRNA expression for any of the target genes. Thus, E2 synergized behaviorally and neurochemically with an SSRI but not a tricyclic antidepressant.

AB - This study investigated estradiol (E2) modulation of the antidepressant effects of a selective serotonin (5-HT) reuptake inhibitor (SSRI; sertraline) and a tricyclic antidepressant (imipramine) as measured by the forced swim test (FST) followed by assessment of gene and protein expression for the 5-HT transporter (SERT) and multiple 5-HT receptors. Female Sprague-Dawley rats were ovariectomized (OVX) and two-thirds of the rats received E2 implants (OVE). 4 weeks later, implants were withdrawn in half of the OVE rats (OVW) to capture a time point when E2 levels were rapidly declining. Rats in each hormone group were treated with vehicle, sertraline (10 mg/kg) or imipramine (10 mg/kg), 24, 5 and 1 h before the FST. Immediately after the FST, midbrain, hippocampus and prefrontal cortex tissue was removed and frozen for analysis of gene expression via quantitative real-time PCR (midbrain tissue) and protein expression via Western blot (prefrontal cortex and hippocampal tissue). In the FST, sertraline decreased immobility and increased swimming in OVE rats, as well as increased swimming in OVW rats. In contrast, no sertraline effect was observed in OVX rats. Rats treated with imipramine showed increased climbing but no changes in immobility or swimming. No changes in protein expression were detected in any treatment group. However, in vehicle-treated rats, E2 increased midbrain SERT mRNA expression, with no effect on midbrain mRNA for the 5-HT receptors. In sertraline-treated rats, E2 decreased 5-HT2A receptor mRNA, and E2-withdrawal increased 5-HT1A, 5-HT2A and 5-HT2C receptor mRNA. In imipramine-treated rats, E2 (and E2-withdrawal) did not affect mRNA expression for any of the target genes. Thus, E2 synergized behaviorally and neurochemically with an SSRI but not a tricyclic antidepressant.

KW - Antidepressant

KW - Estrogen

KW - Forced swim test

KW - Selective serotonin reuptake inhibitor

KW - Serotonin receptors

KW - Serotonin transporter

UR - http://www.scopus.com/inward/record.url?scp=49049115706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49049115706&partnerID=8YFLogxK

U2 - 10.1016/j.psyneuen.2008.05.006

DO - 10.1016/j.psyneuen.2008.05.006

M3 - Article

C2 - 18650020

AN - SCOPUS:49049115706

VL - 33

SP - 1051

EP - 1060

JO - Psychoneuroendocrinology

JF - Psychoneuroendocrinology

SN - 0306-4530

IS - 8

ER -